Dose-dense taxotere (T) and adriamycin/cyclophosphamide (AC) as neoadjuvant treatment in locally advanced breast cancer (LABC).

被引：0
|
作者：
García-Mata, J
Calvo, L
García-Palomo, A
Mel, JR
Almanza, MC
Ramos, M
de Paz, LH
机构：
[1] H Santa Maria Nai, Orense, Spain
[2] H Juan Canalejo, La Coruna, Spain
[3] H Leon, Leon, Spain
[4] H Xeral Calde, Lugo, Spain
[5] Clin Povisa, Vigo, Spain
[6] Ctr Oncol, La Coruna, Spain
[7] H Arquitecto Marcide, Ferrol, Spain
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S226 / S227
页数：2
相关论文
共 50 条
  • [1] Neoadyuvant therapy with dose-dense (DD) docetaxel (T) and doxorubicin/cyclophosphamide (AC) in locally advanced breast cancer (LABC)
    Mata, J. G.
    Antolin, S.
    Mel, J. R.
    Ramos, M.
    Garcia-Palomo, A.
    Almanza, M. C.
    De Paz, L.
    Calvo Martinez, L.
    Alvarez, E.
    Gonzalez-Quintas, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] A Phase 11 study of neoadjuvant chemotherapy (NC) with taxotere, adriamycin and cyclophosphamide (TAC) in locally advanced breast cancer (LABC)
    Lal, A.
    Alidina, A.
    Vaziri, I.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 122 - 122
  • [3] Phase II study of dose-dense docetaxel (T) and epirubicin (E) as neoadjuvant treatment for locally advanced breast cancer (LABC).: An ONCOPAZ Cooperative Group
    Lorenzo, A
    Madroñal, C
    Sanz, JJ
    Centelles, M
    López, MR
    Casas, A
    Péez, VG
    de la Puente, CG
    López, MJG
    Borrega, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 72S - 72S
  • [4] Dose-dense neoadjuvant treatment with biweekly docetaxel (T) plus epirubicin (E) for locally advanced breast cancer (LABC).: An ONCOPAZ Cooperative Group Study.
    Borrega, P
    Lorenzo, A
    Madroñal, C
    Sanz, JJ
    Ruiz, M
    Centelles, M
    Casas, A
    de La Puente, CG
    Perez, V
    González-Barón, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 60S - 60S
  • [5] The farnesyl transferase (FTase) inhibitor (FTI) tipifarnib inhibits FTase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer (LABC).
    Moulder, SL
    Sparano, JA
    Kazi, A
    Wright, J
    Munster, PN
    Vahdat, L
    Minton, S
    Hershman, D
    Diaz, N
    Malafa, M
    Riker, A
    Lee, D
    Pellegrino, C
    Li, T
    Negassa, A
    Sebti, SH
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S227 - S227
  • [6] The farnesyl transferase (FT ase) inhibitor (FTI) tipifarnib inhibits FT ase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer (LABC)
    Sparano, J. A.
    Coppola, D.
    Kazi, A.
    Merajver, S.
    Vahdat, L.
    Li, T.
    Pellegrino, C.
    Munster, P.
    Hoschander, S.
    Hopkins, U.
    Hershman, D.
    Wright, J. J.
    Kleer, C.
    Sebti, S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S230 - S230
  • [7] WHICH IS YOUR CHOICE?; NEOADJUVANT ADRIAMYCIN AND DOXETAXEL (AD) VERSUS ADRIAMYCIN, CYCLOPHOSPHAMIDE AND PACLITAXEL(AC-T) IN LOCALLY ADVANCED BREAST CANCER
    Kang, S. Y.
    Kim, K. S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 135 - 135
  • [8] WHICH IS YOUR CHOICE? NEOADJUVANT ADRIAMYCIN AND DOXETAXEL (AD) VERSUS ADRIAMYCIN, CYCLOPHOSPHAMIDE AND PACLITAXEL (AC-T) IN LOCALLY ADVANCED BREAST CANCER
    Kang, S. Y.
    Choi, J. -H.
    Lee, H. W.
    Ahn, M.
    Kim, K. S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 127 - 127
  • [9] Improved efficacy in the neoadjuvant treatment of locally advanced breast cancer (LABC)
    Smolanka, I. I.
    Lygyrda, O. F.
    Galakhin, K. A.
    Kudrjavetz, Y. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 134 - 134
  • [10] DOSE-DENSE NEOADJUVANT CHEMOTHERAPY IN COMBINED TREATMENT OF IN LOCALLY ADVANCED CERVICAL CANCER: EXPERIENCE AND PROSPECTS
    Bondarev, N.
    Berlev, I.
    Mikaya, N.
    Smirnova, O.
    Bezhanova, E.
    Petrova, A.
    Mishchenko, A.
    Guseynov, K.
    Sidoruk, A.
    Mkrtchyan, H.
    Nekrasov, E.
    Ulrikh, E.
    Urmancheeva, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 884 - 884
12345